在性结肠炎中优化 carotegrast 甲基的使用:患者概况,预测生物标志物和疗效评估时间 (ASPECT 研究)
Katsuyoshi Matsuoka1, Fumihito Hirai2, Kenji Watanabe3
1Division of Gastroenterology and Hepatology, Department of Internal Medicine, Toho University Sakura Medical Center, 564-1, Shimoshizu, Sakura-Shi, Chiba, 285-8741, Japan. matsuoka@fk2.so-net.ne.jp.
卡罗特格拉斯特甲基对中度活跃的性结肠炎有效,特别是在基线疾病活性较低的患者中. 在第2周早期评估和监测抗整体αvβ6抗体标位可以预测治疗反应.
科学领域:
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 卡洛特格拉斯特甲基已批准用于治疗对5-氨酸 (5-ASA) 耐火性性结肠炎 (UC).
- 有限的现实世界数据存在,以优化其使用.
- 这项研究确定了患者个人资料,预测生物标志物和有效性评估的最佳时间.
研究的目的:
- 描述适合 carotegrast 甲基的患者个人资料.
- 确定生物标志物预测 carotegrast 甲基疗效.
- 确定治疗评估的适当时间.
主要方法:
- 从第三阶段试验中对186名患者进行了回顾性分析 (96名卡罗特格拉斯特甲基,90名安慰剂).
- 评估的生物标志物:富含白的α-2糖蛋白,C反应蛋白,便calprotectin,抗整体αvβ6抗体标位.
- 评估临床结果,症状日记和维持疗法.
主要成果:
- 低基线疾病活性 (部分梅奥得分≤5) 与更高的缓解率 (56.1%) 相相关.
- 抗整体αvβ6抗体标位<44.6 U/mL预测更高的缓解率 (49.1%).
- 便calprotectin<387.5μg/g预测内镜愈合 (梅奥内镜子评分0/1). 预测内镜愈合 (梅奥内镜子评分0/1).
结论:
- 卡洛特格拉斯特甲基在UC患者中最有效,其基线疾病活性较低.
- 第二周是评估疗效的适当时间点.
- 反整合素αvβ6抗体标位和便calprotectin显示出预测反应和监测愈合的希望.
更多相关视频
09:01Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice
Published on: March 10, 2015
08:12Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
Published on: March 14, 2019
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
